PSMA6P4

Across TCGA pan-cancer cohorts, PSMA6P4 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated PSMA6P4 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher PSMA6P4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSMA6P4 expression acts as an unfavorable survival marker, although some lineages such as UCS and ESCA show a favorable association.

CHOL, UCEC, and LIHC are the cancer types where PSMA6P4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Tertile	II,III,IV	0.016	0.406	<.001	81	view →
UCEC	DFS	Tertile	All	0.737	0.862	<.001	72	view →
LIHC	OS	Tertile	II,III,IV	0.350	0.679	<.001	57	view →
READ	OS	Tertile	II,III,IV	0.811	0.948	.003	36	view →
OV	DFS	Quartile	All	0.463	0.551	.016	18	view →
UCS	DFS	Tertile	All	0.450	0.162	.015	18	view →
KICH	OS	Tertile	II,III,IV	0.740	0.966	.012	12	view →
ESCA	OS	Median	IV	0.698	0.222	.006	12	view →
LUAD	DFS	Tertile	All	0.523	0.257	.006	12	view →
LGG	OS	Quartile	All	0.878	0.764	.023	11	view →
THCA	DFS	Tertile	IV	0.585	0.819	.032	9	view →
BLCA	OS	Tertile	All	0.338	0.463	.046	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

PSMA6P4–CHOL (DFS)

Open the CHOL breakdown →